Acasti Pharma Inc  

(Public, CVE:APO)   Watch this stock  
Find more results for APO
+0.010 (1.64%)
Delayed:   9:31AM EST
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.62 - 0.62
52 week 0.41 - 1.54
Open 0.62
Vol / Avg. 3,100.00/59,531.00
Mkt cap 66.00M
P/E     -
Div/yield     -
EPS -0.02
Shares 106.44M
Beta 1.31
Inst. own     -
Jan 13, 2015
Q3 2014 Acasti Pharma Inc Earnings Release

Key stats and ratios

Q4 (Nov '14) 2014
Net profit margin 10449.96% -2318.25%
Operating margin -10286.36% -2156.14%
EBITD margin - -1802.00%
Return on average assets 30.06% -40.18%
Return on average equity 35.81% -54.00%
CDP Score - -


100-545 Prom du Centropolis
+1-450-6864555 (Phone)
+1-450-6862505 (Fax)

Website links


Acasti Pharma Inc. (Acasti) is engaged in developing a product portfolio of long-chain omega-3 phospholipids. Acasti is a majority owned subsidiary of Neptune Technologies and Bioressources Inc. (Neptune). The Company has one operating segment: the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. The Company�s product portfolio includes concentrated phospholipids which functionalize eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Acasti is the producer of anti-dyslipidemic prescription drugs (CaPre), medical foods (Onemia) and over-the-counter (OTC) products (Vectos). During the fiscal year ended February 28, 2011 (fiscal 2011), the Company has completed the development and launched medical food, Onemia.

Officers and directors

Jerald J. Wenker Chairman of the Board
Andre Godin Interim President and Chief Executive Officer
Pierre Lemieux Ph.D. Chief Operating Officer
Harlan W. Waksal M.D. Executive Vice President - Business and Scientific Affairs, Director
Age: 60
Tina Sampalis MD., Ph.D. Chief Global Strategy Officer
Ronald Denis Director
Henri Harland Director
Valier Boivin Independent Director
Jean-Claude Debard Independent Director
Reed V. Tuckson M.D. Independent Director